![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/en/thumb/a/ac/GW_Pharmaceuticals_logo.svg/640px-GW_Pharmaceuticals_logo.svg.png&w=640&q=50)
GW Pharmaceuticals
From Wikipedia, the free encyclopedia
GW Pharmaceuticals Limited[1] is a British pharmaceutics company known for its multiple sclerosis treatment product nabiximols (brand name, Sativex) which was the first natural cannabis plant derivative to gain market approval in any country.[3] Another cannabis-based product, Epidiolex, was approved for treatment of epilepsy by the US Food and Drug Administration in 2018.[4] It is a subsidiary of Jazz Pharmaceuticals.
Quick Facts Formerly, Company type ...
![]() | |
Formerly |
|
---|---|
Company type | Subsidiary |
Industry | Pharmaceutical industry |
Founded | 1998; 26 years ago (1998) |
Founder |
|
Headquarters | Cambridge, United Kingdom |
Key people | Justin Gover (CEO) |
Products |
|
Revenue | ![]() |
![]() | |
Total assets | ![]() |
Total equity | ![]() |
Number of employees | 1,161 (2020) |
Parent | Jazz Pharmaceuticals |
Website | gwpharm![]() |
Footnotes / references [2] |
Close